Previous 10 | Next 10 |
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous...
2024-01-25 04:45:00 ET Summary Patient Capital Management are long-term, contrarian, value investors focusing on growing wealth through Time, not Timing. We operate with the singular purpose of serving clients and helping them enhance their long term investment returns. The strate...
2024-01-22 07:13:56 ET Summary Royalty Pharma is a unique pharmaceutical company that diversifies investments in market-leading or late-stage development therapies. RPRX has a dominant position in the pharmaceutical royalty market and shares in the profits of successful pharmaceut...
2024-01-19 08:24:57 ET More on Royalty Pharma Royalty Pharma: Post Q3 Earnings, We Reiterated Our Strong Buy Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript Teva inks $125M deal with Royalty Pharma to develop antipsychotic drug Royalty Pharma Q3 20...
2024-01-11 04:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range Announced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025 NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ...
2023-12-24 21:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6 th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Ph...
2023-11-13 09:51:59 ET More on Royalty Pharma, Teva, etc. Royalty Pharma: Post Q3 Earnings, We Reiterated Our Strong Buy Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. ...
News, Short Squeeze, Breakout and More Instantly...
Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This co...
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 202...
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases...